Literature DB >> 19385600

Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression.

Cédric Charrier1, Jonathan Clarhaut, Jean-Pierre Gesson, Guillermina Estiu, Olaf Wiest, Joëlle Roche, Philippe Bertrand.   

Abstract

New benzofuranones were synthesized and evaluated toward NCI-H661 non-small cell lung cancer cells. Benzamide derivatives possessed micromolar antiproliferative and histone deacetylase inhibitory activities and modulate histone H4 acetylation. Hydroxamic acids were found to be potent nanomolar antiproliferative agents and HDAC inhibitors. Computational analysis presented a rationale for the activities of the hydroxamate derivatives. Impact of the HDAC inhibition on the expression of E-cadherin and the SEMA3F tumor suppressor genes revealed new promising compounds for lung cancer treatments.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19385600     DOI: 10.1021/jm9002439

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Multicatalytic, asymmetric Michael/Stetter reaction of salicylaldehydes and activated alkynes.

Authors:  Claire M Filloux; Stephen P Lathrop; Tomislav Rovis
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-16       Impact factor: 11.205

2.  Syntheses of mycobactin analogs as potent and selective inhibitors of Mycobacterium tuberculosis.

Authors:  Raúl E Juárez-Hernández; Scott G Franzblau; Marvin J Miller
Journal:  Org Biomol Chem       Date:  2012-08-16       Impact factor: 3.876

Review 3.  Epigenetic polypharmacology: A new frontier for epi-drug discovery.

Authors:  Daniela Tomaselli; Alessia Lucidi; Dante Rotili; Antonello Mai
Journal:  Med Res Rev       Date:  2019-06-20       Impact factor: 12.944

4.  New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.

Authors:  Fabien Gueugnon; Pierre-François Cartron; Cedric Charrier; Philippe Bertrand; Jean-François Fonteneau; Marc Gregoire; Christophe Blanquart
Journal:  Oncotarget       Date:  2014-06-30

5.  Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor Therapy.

Authors:  Fatima El Bahhaj; Iza Denis; Loic Pichavant; Régis Delatouche; Floraine Collette; Camille Linot; Daniel Pouliquen; Marc Grégoire; Valérie Héroguez; Christophe Blanquart; Philippe Bertrand
Journal:  Theranostics       Date:  2016-03-25       Impact factor: 11.556

6.  Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.

Authors:  Douae Bensaid; Thibaut Blondy; Sophie Deshayes; Virginie Dehame; Philippe Bertrand; Marc Grégoire; Mohammed Errami; Christophe Blanquart
Journal:  Clin Epigenetics       Date:  2018-06-18       Impact factor: 6.551

7.  Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.

Authors:  Yudibeth Sixto-López; José Antonio Gómez-Vidal; Nuria de Pedro; Martiniano Bello; Martha Cecilia Rosales-Hernández; José Correa-Basurto
Journal:  Sci Rep       Date:  2020-06-26       Impact factor: 4.379

Review 8.  The ROMP: A Powerful Approach to Synthesize Novel pH-Sensitive Nanoparticles for Tumor Therapy.

Authors:  Philippe Bertrand; Christophe Blanquart; Valérie Héroguez
Journal:  Biomolecules       Date:  2019-02-12

9.  Hydroxamic acid - A novel molecule for anticancer therapy.

Authors:  Dilipkumar Pal; Supriyo Saha
Journal:  J Adv Pharm Technol Res       Date:  2012-04

Review 10.  HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?

Authors:  Claudia Simões-Pires; Vincent Zwick; Alessandra Nurisso; Esther Schenker; Pierre-Alain Carrupt; Muriel Cuendet
Journal:  Mol Neurodegener       Date:  2013-01-29       Impact factor: 14.195

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.